Year All202620252024202320222021 Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) 03-20-2026 Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million 03-16-2026 Zevra Reports Fourth Quarter and Full Year 2025 Financial Results 03-09-2026 Zevra Therapeutics Appoints Justin Renz as Chief Financial Officer 03-05-2026 Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call 03-02-2026 Zevra Therapeutics to Present at the Citizens Life Sciences Conference 02-25-2026 Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™ 02-04-2026 Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026 02-02-2026 Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™ 01-26-2026 Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference 01-08-2026
Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) 03-20-2026
Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™ 02-04-2026
Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™ 01-26-2026
